Britannia Life Sciences Inc. (CSE:BLAB)

Revenue by Segment

Financials in millions CAD. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Medical Labs & Research	369.28K	516.83K	6.40M	7.30M	1.42M
Medical Labs & Research Growth	-28.55%	-91.93%	-12.28%	412.42%	-
Total	369.28K	516.83K	6.40M	7.30M	1.42M
Total Growth	-28.55%	-91.93%	-12.28%	412.42%	-

Revenue by Geography

Financials in millions CAD. Fiscal year is April - March.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
United States	369.28K	516.83K	6.40M	7.30M	1.42M
United States Growth	-28.55%	-91.93%	-12.28%	412.42%	-
Total	369.28K	516.83K	6.40M	7.30M	1.42M
Total Growth	-28.55%	-91.93%	-12.28%	412.42%	-

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 17, 2026

Data Sources Report a data error